CJC/IPA 5/5MG

The DAC linker on CJC-1295 is an N-ε-3-maleimidopropionyl (MPA) group attached to the ε-amine of Lys29 at the C-terminus. After subcutaneous injection, the maleimide group undergoes a thio-Michael addition with the free thiol of serum albumin Cys-34 (the only free cysteine in circulating albumin), forming a stable, irreversible thioether bond. [1]

2. GHRHr Signaling Cascade

CJC-1295 engages the GHRH receptor (GHRHr), a class B G protein-coupled receptor expressed on anterior pituitary somatotroph cells: [2]

• Gs/cAMP pathway: GHRHr → Gs → adenylyl cyclase → cAMP ↑ → PKA activation → phosphorylation of CREB → GH gene transcription
• IP3/Ca²⁺ pathway: Secondary Gq coupling → PLC → IP3 → intracellular Ca²⁺ mobilization → GH vesicle exocytosis
• IGF-1 loop: GH → liver → IGF-1 production → peripheral tissues (muscle, bone, adipose) → anabolic signaling
• Negative feedback: Rising IGF-1 and somatostatin suppress further GH release — preserving physiological regulation

3. CJC-1295 with DAC vs. No-DAC vs. Native GHRH

4. DNA Damage Considerations

Preclinical research (Ben-Shlomo et al., 2020) has raised the hypothesis that sustained, continuous GH stimulation via long-acting GHRH analogues may promote DNA damage in pituitary somatotroph cells — a potential concern with tonic GH elevation unlike the physiological pulsatile pattern. [6] This remains an active area of mechanistic research and is not yet established as a clinical safety signal from human trial data.

CJC-1295 has been investigated as an alternative to daily rhGH injections for adults with GHD or age-related somatopause. Phase I data (Teichman et al., 2006) in healthy adults (n=64) demonstrated that a single SC injection produced dose-dependent GH increases (1.5 to 3-fold above baseline) lasting 9–11 days, with IGF-1 increases of 1.3 to 1.9-fold sustained for 9–11 days. [3] This durability profile positions CJC-1295 with DAC as a potential once-weekly or biweekly pituitary secretagogue in GHD research models.

🔬 Body Composition Research

GH and IGF-1 regulate body composition by stimulating lipolysis (fat breakdown) and protein synthesis (muscle anabolism). Preclinical studies in rodent models demonstrate that sustained GHRH receptor activation increases lean body mass and reduces adipose tissue — effects mediated via IGF-1 signaling in muscle and fat tissue. [5] CJC-1295 with DAC produces continuous IGF-1 elevation that may amplify these body composition effects compared to pulsatile delivery approaches.

🔬 Metabolic Research — HIV-Associated Lipodystrophy

Phase II trials in adults with HIV-associated lipodystrophy (fat redistribution syndrome) were initiated by ConjuChem before the company's closure. This population was selected because HIV antiretroviral therapy causes peripheral fat loss and central fat accumulation, with secondary GH axis suppression. CJC-1295 with DAC was hypothesized to restore GH/IGF-1 physiology and normalize fat distribution — a clinically meaningful endpoint in this population. [4] Development was discontinued without publication of Phase II results.

🔬 Pediatric GHD (Preclinical Model)

Alba et al. (2006) studied GRF analogues in GH-deficient rat models, establishing the preclinical basis for dosing regimens translatable to pediatric GHD research. CJC-1295 with DAC showed dose-dependent normalization of growth parameters in hypophysectomized rodents — the standard in vivo model for GHD. [7]

🔬 Pituitary Biology and GH Axis Research

CJC-1295 with DAC serves as a pharmacological tool compound for studying tonic vs. pulsatile GH axis stimulation. Because it provides continuous, week-long GHRHr activation, it enables researchers to decouple the effects of GH pulse frequency from GH pulse amplitude — questions relevant to optimizing GH replacement therapy dosing regimens. [2]